NCT06018688View on ClinicalTrials.gov

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

September 1, 2026

Conditions
Non Small Cell Lung CancerEGFR Gene Mutation
Interventions
DRUG

Osimertinib

Osimertinib is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.

DRUG

Aspirin

Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation.

All Listed Sponsors
lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

NCT06018688 - Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. | Biotech Hunter | Biotech Hunter